BCG疫苗接种试验的自然揭盲问题
结论认为需详细描述克服揭盲障碍的策略以解释理论设盲试验。
要点
- BCG注射后数天出现皮肤反应,难以对受试者设盲。
- 94.7%的BCG防COVID-19试验标注安慰剂对照且设盲,但未说明克服揭盲的方法。
- 需明确描述克服皮肤反应所致揭盲的策略以合理解释设盲试验结果。
核心结论
- BCG疫苗接种诱导的皮肤反应导致自然揭盲,注册试验未说明克服策略,影响设盲试验的解释。
主要发现
- 94.7%的BCG防COVID-19试验标注为安慰剂对照,安慰剂均为生理盐水,设盲方式为单盲至四盲。
- 所有试验均未在网站上说明克服BCG皮肤反应所致揭盲的方法。
临床怎么用
- 解读BCG防COVID-19设盲试验时,需关注是否报告克服皮肤反应揭盲的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is significant public and clinical interest in the potential for Bacillus Calmette-Guérin (BCG) vaccination to protect against type 2 Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) induced COVID-19. This question could be best answered by blinded and placebo controlled clinical trials. However, a skin reaction occurs within days at the site of BCG injection, making it rather challenging to blind this vaccination. Here, we examined registered clinical trials in ClinicalTrials.gov on BCG against COVID-19 by October 9th 2020, and found that 94.7% of such trials were listed as placebo controlled (all with normal saline as placebo), and single to quadruple blinded. The mode of overcoming the natural unblinding by the BCG induced skin reaction was not clarified on the website in either of the trials. We conclude that detailed description of the strategy towards overcoming the BCG vaccination induced skin reaction associated unblinding hurdle will be important for the interpretation of the theoretically blinded COVID-19 directed clinical trials.
引用
- Szigeti R, Kellermayer R. Natural unblinding of BCG vaccination trials. Vaccine. 2021. PMID: 33744042. doi:10.1016/j.vaccine.2021.03.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。